Remicade infliximab: Marketed

In the double-blind North American and European Phase III ASPIRE study in 1049 patients, 3 and 6 mg/kg doses of Remicade plus methotrexate (MTX) met the 3 co-primary endpoints compared to MTX alone at week

Read the full 354 word article

How to gain access

Continue reading with a
two-week free trial.